MINI-FUTURE SHORT - ELI LILLY & CO | Real-time Bid/Ask 03:39:55 2024-07-02 EDT | ||
| 1.48 CHF / 1.51 CHF | -0.33% |
|
| Current month | -1.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 1.5 | -1.96% |
| 24-06-28 | 1.53 | -5.56% |
| 24-06-27 | 1.62 | +0.62% |
| 24-06-26 | 1.61 | +3.21% |
| 24-06-25 | 1.56 | -6.59% |
Delayed Quote Swiss Exchange
Last update July 01, 2024 at 11:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| UBGCSU | |
| ISIN | CH1350821596 |
| Date issued | 2024-06-14 |
| Strike | 1,079 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 1.74 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.78 CHF |
|---|---|
| Lowest since issue | 1.5 CHF |
| Spread | 0.03 CHF |
| Spread % | 1.97% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Certificates
- UBGCSU Certificat
